Mediport use as an acceptable standard for CAR T cell infusion

INTRODUCTION: Mediport use as a clinical option for the administration of chimeric antigen receptor T cell (CAR T cell) therapy in patients with B-cell malignancies has yet to be standardized. Concern for mediport dislodgement, cell infiltration, and ineffective therapy delivery to systemic circulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Eylon, Maya, Prabhu, Snehit, John, Samuel, King, Maxwell J. M., Bhatt, Dhruv, Curran, Kevin J., Erickson, Courtney, Karras, Nicole A., Phillips, Christine L., Satwani, Prakash, Hermiston, Michelle, Southworth, Erica, Baumeister, Susanne H. C., Talano, Julie-An, MacMillan, Margaret L., Rossoff, Jenna, Bonifant, Challice L., Myers, Gary Doug, Rouce, Rayne H., Toner, Keri, Driscoll, Timothy A., Katsanis, Emmanuel, Salzberg, Dana B., Schiff, Deborah, De Oliveira, Satiro N., Capitini, Christian M., Pacenta, Holly L., Pfeiffer, Thomas, Shah, Niketa C., Huynh, Van, Skiles, Jodi L., Fraint, Ellen, McNerney, Kevin O., Quigg, Troy C., Krueger, Joerg, Ligon, John A., Fabrizio, Vanessa A., Baggott, Christina, Laetsch, Theodore W., Schultz, Liora M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642031/
https://www.ncbi.nlm.nih.gov/pubmed/37965315
http://dx.doi.org/10.3389/fimmu.2023.1239132

Ejemplares similares

Ejemplares similares